Chap57N RCC

  1. Risk factors for RCC?
    Image Upload 1
  2. Cell of origin for RCC?
    PCT - clear cell and papillary variants

    DCT - chromophobe and collecting duct RCC
  3. Familial Renal Cell Carcinoma (RCC) Syndromes?
    Image Upload 2
  4. Manifestations of the von Hippel-Lindau Syndrome?
    Image Upload 3
  5. Short note on VHL gene?
    • - Tumor suppressor gene
    • - Located at chromosome 3p25-26
    • - As with most tumor suppressor genes, both alleles of the VHL gene must be mutated or inactivated for development of the disease; the observed inheritance patterns have conformed to Knudson’s hypotheses.
  6. Role of VHL protein complex in RCC?
    • To target the hypoxia-inducible factors 1 and2 (HIF-1 and HIF-2) for ubiquitin-mediated degradation,keeping the levels of HIFs low under normal conditions.
    • Inactivation or mutation of the VHL gene leads to dysregulated expression of the HIFs, and they begin to accumulate in the cell.
    • This, in turn, leads to a several fold upregulation of the expression of VEGF, the primary angiogenic growth factor in RCC, contributing to the pronounced neovascularity associated with clear cell RCC
  7. Pathology of RCC?
    • Round to ovoid and circumscribed by a pseudocapsule of compressed parenchyma and fibrous tissue rather than a true histologic capsule.
    • Unlike upper tract TCC, most RCCs are not grossly infiltrative, with the notable exception of collecting duct RCC and some sarcomatoid variants.
    • All RCCs are, by definition, adenocarcinomas, derived from renal tubular epithelial cells
  8. Differentiation between benign and malignant RCC?
    With the exception of oncocytomas and some small (<1 cm) low-grade papillary adenomas, there are no reliable histologic or ultrastructural criteria to differentiate benign from malignant renal epithelial tumors
  9. Fuhrman’s Classification System for Nuclear Grade in Renal Cell Carcinoma?
    Image Upload 4
  10. Pathologic Subtypes of RCC?
    • Clear cell RCC (70%-80%)
    • Multilocular cystic clear cell RCC (uncommon)
    • Papillary RCC (10%-15%)
    • Chromophobe RCC (3%-5%)
    • Collecting duct carcinoma (<1%)
    • Renal medullary carcinoma (rare) 
    • Unclassified RCC(1%-3%)
  11. Important features of clear cell RCC?
    • - Well circumscribed and a capsule is usually absent
    • - Typically yellow when theyare bivalved and are highly vascular
    • - Patients with clear cell RCC have a worse prognosis compared with papillary or chromophobe RCC, even after stratification for stage and grade. 
    • - Chromosome 3 alterations and VHL mutations are common in clear cell RCC, and mutation or inactivation of this gene has been found in a majority of sporadic cases
  12. Important features of Papillary Renal Cell Carcinoma?
    • - Macroscopically, pRCC is well circumscribed with a pseudocapsule, yellow or brown in colour, and a soft structure.
    • - more commonly found in patients with end-stage renal failure and acquired renal cystic disease.
    • - tendency to multicentricity
    • - The cytogenetic abnormalities associated with papillary RCC are characteristic and include trisomy of chromosomes 7 and 17 and loss of the Y chromosome
  13. Features of chromophobe RCC?
    • -  derived from the cortical portion of the collecting duct
    • - Chromophobe RCC cannot be graded (by the Fuhrman grading system), because of its innate nuclear atypia
    • - a perinuclear clearing or “halo” is typically found and electron microscopic findings consist of numerous 150-to 300-nm microvesicles, which are the single most distinctive and defining feature of chromophobe cell carcinoma
    • - Loss of chromosomes Y, 1, 2, 6, 10, 13, 17 and 21 are typical genetic changes
    • - These microvesicles characteristically stain positive for Hale colloidal iron, indicating the presence of a mucopolysaccharide unique to chromophobe RCC
  14. Renal medullary carcinoma?
    • -  a very rare tumour, comprising < 0.5% of all RCCs,
    • - is predominantly diagnosed in young adults (median age 28 years) with sickle haemoglobinopathies (including sickle cell trait).
    • - Renal medullary carcinoma is one of the most aggressive RCCs and most patients (~67%) will present with metastatic disease
  15. Treatment of renal medullary carcinoma?
    • Despite treatment, median OS is 13 months in the most recent series.
    • Due to the infiltrative nature and medullary epicentre of RMC, radical nephrectomy is favoured over partial nephrectomy even in very early-stage disease.
  16. Clinical features of RCC?
    Many renal masses remain asymptomatic and non-palpable until they are advanced.

    Image Upload 5
  17. Classic triad of RCC?
    • Flank pain
    • Gross hematuria
    • Palpable abdominal mass

    - rarely found - a too late triad.
  18. Physical examination finding in RCC?
    • • palpable abdominal mass;
    • • palpable cervical lymphadenopathy;
    • • non-reducing varicocele and bilateral lower extremity oedema, which suggests venous involvement
  19. Renal Nephrometry score?
    Image Upload 6
  20. TNM of RCC?
    • T1 - ≤ 7 cm, limited to kidney
    • T1a - ≤ 4 cm
    • T1b - 4 cm- 7 cm

    • T2 - > 7 cm, limited to the kidney
    • T2a - 7-10 cm
    • T2b - > 10 cm

    • T3 - extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond Gerota fascia
    • T3a - into the renal vein or its segmental branches, or tumour invades perirenal and/or renal sinus fat
    • T3b - into the vena cava below diaphragm
    • T3c -  into vena cava above the diaphragm or invades the wall of the vena cava

    T4 - beyond Gerota fascia (including contiguous extension into the ipsilateral adrenal gland
  21. Updates in the American Joint Committee on Cancer staging of kidney cancer?
    Image Upload 7
  22. Uncertainties of TNM staging?
    • • The sub-classification of T1 tumours using a cut-off of 4 cm might not be optimal in NSS for localised cancer.
    • • The value of size stratification of T2 tumours has been questioned.
    • • Since the 2002 version, tumours with renal sinus fat invasion have been classified as pT3a.
    • • Renal sinus fat invasion might carry a worse prognosis than perinephric fat invasion but is nevertheless included in the same pT3a stage group.
    • • Sub T-stages (pT2b, pT3a, pT3c and pT4) may overlap [99].
    • • For adequate M staging, accurate pre-operative imaging (chest and abdominal CT) should be performed
  23. Paraneoplastic syndromes with RCC?
    - Found in 20% of patients with RCC - RCC was previously referred to as the internist’s tumor because of the predominance of systemic rather than local manifestations. Now, a more appropriate name would be the radiologist’s tumor. 

    • Hypercalcemia 
    • - 13% of patients with RCC
    • - due to either paraneoplastic phenomena (PTH like peptides) or osteolytic metastatic involvement of the bone.

    Hypertension - secondary to increased production of renin directly by the tumor; compression or encasement of the renal artery or its branches, effectively leading to renal artery stenosis;or arteriovenous fistula within the tumor

    Polycythemia - due to increased production of erythropoietin, either directly by the tumor or by the adjacent parenchyma in response to hypoxia. 

    Nonmetastatic hepatic dysfunction,or Stauffer syndrome.
  24. Medical management of Hypercalcemia?
    Medical management predominatesand includes vigorous hydration followed bydiuresis with furosemide and the selective use of bisphosphonates,corticosteroids, or calcitonin (reviewed in Goldet al, 1996; Coleman, 2004; Pepper et al, 2007; Schwarzberg andMichaelson, 2009). Bisphosphonate therapy is now establishedas standard of care for patients with hypercalcemiaof malignancy, as long as renal function is adequate. Zoledronic acid, 4 mg intravenouslyevery 4 weeks
  25. Treatment of Paraneoplastic syndrome?
    In general, treatment of paraneoplastic syndromesassociated with RCC has required surgical excision orsystemic therapy and, except for hypercalcemia, medicaltherapies have not proved helpful
  26. Radiological investigations for RCC? (EAU 18)
    • CECT - >15 HUs enhancement suggestive of RCC.
    • MRI - for venous involvement if the extent of an inferior vena cava (IVC) tumour thrombus is poorly defined on CT.
    • For the diagnosis of complex renal cysts (Bosniak IIF-III), contrast-enhanced ultrasonography showed high sensitivity (100%) and specificity (97%), with a negative predictive value of 100%.
    • Chest CT is accurate for chest staging.
    • There is a consensus that most bone metastases are symptomatic at diagnosis; thus, routine bone imaging is not generally indicated
  27. Indication of biopsy in RCC? - EAU
    • • to obtain histology of radiologically indeterminate renal masses;
    • • to select patients with small renal masses for active surveillance;
    • • to obtain histology before, or simultaneously with, ablative treatments;
    • • to select the most suitable form of medical and surgical strategy in the setting of metastatic disease
  28. Management of RCC? - EAU
    • Treatment of localised RCC
    • - Offer partial nephrectomy to patients with T1 tumours
    • - If no adrenal gland involvement - do not perform ipsilateral adrenalectomy 
    • - If large tumor, extended LN dissection 
    • - RN in T2 tumors 

    • Treatment of Locally advanced RCC
    • - In patients with clinically enlarged lymph nodes, perform lymph node dissection for staging purposes or local control.

    • For Metastatic disease - 
    • - Cytoreductive nephrectomy (in favrourable and intermediate risk patients) is palliative and systemic treatments are necessary. 
    • - Do not offer chemotherapy as first-line therapy in patients with clear-cell metastatic RCC.
  29. Surveillance after Radical or Partial
    • Image Upload 8
    • Image Upload 9
  30. Alternatives to surgery? - EAU
    Offer active surveillance, radiofrequency ablation and cryoablation to elderly and/orcomorbid patients with small renal masses.
  31. management of RCC with venous tumour
    • In patients with clinically enlarged lymph nodes, perform lymph node dissection for staging purposes or local control.
    • In case of venous involvement, remove the renal tumour and thrombus.
  32. Immunotherapy in mRCC?  EAU
    • Use ipilimumab plus nivolumab intreatment-naïve patients with clear-cell mRCC of IMDC intermediate and poor risk.
    • Offer nivolumab after one or two lines of VEGF-targeted therapy in mRCC. 
    • Do not rechallange patients who stop nivolumab plus ipilimumab because of toxicity with the same drugs in the future without expert guidance and support from a multidisciplinary team.
  33. Targeted therapies? - EAU
    Use sunitinib or pazopanib in treatmentnaïvepatients with clear-cell mRCC ofIMDC favourable risk.
  34. Updated EAU Guidelines recommendations for the treatment of first-line clear-cell metastatic renal cancer?
    Image Upload 10

    IMDC = The International Metastatic Renal Cell Carcinoma Database Consortium
Card Set
Chap57N RCC